溃疡性结肠炎
医学
外渗
药理学
活性代谢物
代谢物
敌手
细胞粘附分子
内科学
免疫学
药代动力学
受体
疾病
出处
期刊:Drugs
[Springer Nature]
日期:2022-06-01
卷期号:82 (9): 1011-1016
被引量:4
标识
DOI:10.1007/s40265-022-01732-0
摘要
Carotegrast methyl (Carogra®) is a small-molecule α4 integrin antagonist being developed by EA Pharma (formerly Ajinomoto Pharmaceuticals) and Kissei Pharmaceutical for the treatment of ulcerative colitis. The active metabolite of carotegrast methyl exerts an anti-inflammatory effect by blocking the interaction of α4β1 or α4β7 integrins and their ligands, VCAM-1 and MAd-CAM-1, thereby inhibiting the adhesion of inflammatory cells, including T cells, to vascular endothelial cells and extravasation into inflammatory sites. In March 2022, carotegrast methyl received its first approval in Japan for the treatment of moderate ulcerative colitis in patients who had inadequate response to 5-aminosalicylic acid. This article summarizes the milestones in the development of carotegrast methyl leading to this first approval for the treatment of moderate ulcerative colitis.
科研通智能强力驱动
Strongly Powered by AbleSci AI